½ÃÀ庸°í¼­
»óǰÄÚµå
1368649

¸ðÀ¯ ¿Ã¸®°í´ç(HMO) ½ÃÀå ±Ô¸ð : ³óµµº°, ¿ëµµº°, ¼¼°è ¿¹Ãø(2023-2032³â)

Human Milk Oligosaccharides (HMO) Market Size - By Concentration (Neutral HMO, Acidic HMO), By Application (Infant Formula, Dietary Supplements, Food and Beverage) & Global Forecast, 2023 - 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 120 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ¸ðÀ¯ ¿Ã¸®°í´ç(HMO) ½ÃÀåÀº 2023-2032³â 22.5%ÀÇ CAGR·Î ¼ºÀåÇÕ´Ï´Ù.

À¯¾ÆÀÇ ¸é¿ªÃ¼°è ¹ß´Þ°ú Àå °Ç°­¿¡¼­ÀÇ ¿ªÇÒ°ú °°Àº ÀÎüÀ¯·¡ ¿Ã¸®°í´ç(HMOs)ÀÇ °Ç°­»óÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ »ê¾÷ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀÔ´Ï´Ù.

¶ÇÇÑ À¯´çºÒ³»Áõ À¯º´·ü Áõ°¡¿Í À¯¾ÆÀÇ ¸ðÀ¯ ¼öÀ¯·ÎÀÇ ÀüȯÀº ¸ðÀ¯ ¿Ã¸®°í´ç(HMO) ±â¹Ý ºÐÀ¯ ÆÇ¸Å¸¦ Áõ°¡½Ãų °ÍÀ̸ç, MedlinePlusÀÇ ÃßÁ¤¿¡ µû¸£¸é Àα¸ÀÇ ¾à 65%°¡ À¯¾Æ±â¿¡ À¯´çÀ» ¼ÒÈ­ÇÏ´Â ´É·ÂÀÌ ÀúÇϵǾî ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¼ºÀÎ ¿µ¾çÇÐ ¹× ÀǾàǰ°ú °°Àº ºÐ¾ß¿¡¼­ Àΰ£ ¸ðÀ¯ ¿Ã¸®°í´ç(HMO)ÀÇ ÀáÀçÀû ÀÀ¿ë¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¿¬±¸´Â ºñÁî´Ï½º ¼ºÀåÀÇ »õ·Î¿î ±âȸ¸¦ âÃâÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¸ðÀ¯ ¿Ã¸®°í´ç Á¦Á¶¾÷ü¿Í À¯¾Æ¿ë Á¶Á¦ºÐÀ¯ Á¦Á¶¾÷ü°£ÀÇ Á¦ÈÞ ¹× Çù·Â °ü°è Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» ´õ¿í È®´ëÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀº À¯¾Æ¿ë ¿µ¾ç Á¦Ç°¿¡ ¸ðÀ¯ ¿Ã¸®°í´ç(HMO)À» ÷°¡ÇÏ´Â °Í¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ÁöÁö°¡ Áö¼ÓÀûÀ¸·Î ¹ßÀüÇÔ¿¡ µû¶ó º¸¿ÏµÉ °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Çù·Â °ü°è¿Í ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀº ¾÷°è ¼ºÀåÀ» °¡¼ÓÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ»ÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

½ÃÀåÀº ³óµµ, ¿ëµµ ¹× Áö¿ª¿¡ µû¶ó ºÐ·ùµË´Ï´Ù.

³óµµ ±âÁØÀ¸·Î »ê¼º HMO ºÎ¹®Àº 2032³â±îÁö »ó´çÇÑ CAGRÀ» ¹Ý¿µÇÒ °ÍÀÔ´Ï´Ù. »ê¼º HMOÀÇ °Ç°­»óÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í, Ư¼ö À¯¾Æ ¿µ¾ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϸç, À¯¾Æ °Ç°­¿¡ ´ëÇÑ ÀÌÁ¡À» ÀÔÁõÇÏ´Â Áö¼ÓÀûÀÎ ¿¬±¸°¡ ÁøÇàµÇ¸é¼­ ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀÔ´Ï´Ù.

¿µ¾ç º¸ÃæÁ¦ ¿ëµµ´Â 2032³â±îÁö ¸ðÀ¯ ¿Ã¸®°í´ç(HMO) ½ÃÀå¿¡¼­ ÁÖ¸ñÇÒ ¸¸ÇÑ Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, HMOÀÇ ÀáÀçÀûÀÎ °Ç°­»óÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ ÀνÄÀÌ ³ô¾ÆÁö°í, ÀÔÁõµÈ ÇÁ¸®¹ÙÀÌ¿Àƽ½º Ư¼º, ±â´É¼º ¹× ¿µ¾ç º¸ÃæÁ¦, ƯÈ÷ Àå °Ç°­ ¹× ¸é¿ª·Â °­È­¿¡ ÃÊÁ¡À» ¸ÂÃá ±â´É¼º ¹× ¿µ¾ç º¸ÃæÁ¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

Áö¿ªÀûÀ¸·Î ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¸ðÀ¯ ¿Ã¸®°í´ç(HMO) ½ÃÀåÀº Ãâ»êÀ² Áõ°¡, °¡Ã³ºÐ ¼Òµæ Áõ°¡, ¿µ¾Æ ¿µ¾ç¿¡ ´ëÇÑ Á߿伺 Áõ°¡ µîÀÇ ¿äÀο¡ ÈûÀÔ¾î ºÐ¼® ±â°£ Áß ÄªÂùÇÒ ¸¸ÇÑ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¶ÇÇÑ ¸ðÀ¯ ¼öÀ¯ÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í °í±Þ À¯¾Æ¿ë Á¶Á¦ ºÐÀ¯ Á¦Ç°ÀÇ Ã¤ÅÃÀº Áö¿ª »ê¾÷ÀÇ ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¸ðÀ¯ ¿Ã¸®°í´ç(HMO) »ê¾÷ ÀλçÀÌÆ®

  • ¿¡ÄڽýºÅÛ ºÐ¼®
  • ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ÃËÁø¿äÀÎ
    • ¾÷°èÀÇ ÀáÀçÀû ¸®½ºÅ© & °úÁ¦
  • ¼ºÀåÀÇ °¡´É¼º ºÐ¼®
  • COVID-19 ¿µÇ⠺м®
  • ±ÔÁ¦ »óȲ
    • ¹Ì±¹
    • À¯·´
  • °¡°Ý ºÐ¼®, 2022³â
  • ±â¼ú Àü¸Á
    • ÇâÈÄ ½ÃÀå µ¿Çâ
  • PorterÀÇ »ê¾÷ ºÐ¼®
  • PESTEL ºÐ¼®
  • ·¯½Ã¾Æ¡¤¿ìÅ©¶óÀ̳ª ÀüÀïÀÇ ¿µÇâ

Á¦4Àå °æÀï ±¸µµ

  • ¼­·Ð
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • ¼¼°è ±â¾÷ Á¡À¯À² ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå ¸ðÀ¯ ¿Ã¸®°í´ç(HMO) ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ³óµµº°, 2018-2032³â

  • Áß¼º HMO
  • »ê¼º HMO

Á¦6Àå ¸ðÀ¯ ¿Ã¸®°í´ç(HMO) ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ¿ëµµº°, 2018-2032³â

  • À¯¾Æ¿ë Á¶Á¦ºÐÀ¯
  • ½ÄÀ̺¸ÃæÁ¦
  • ½Äǰ ¹× À½·á
  • ±âŸ

Á¦7Àå ¸ðÀ¯ ¿Ã¸®°í´ç(HMO) ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°, 2018-2032³â

  • ÁÖ¿ä µ¿Çâ : Áö¿ªº°
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • Àεµ³×½Ã¾Æ
    • ¸»·¹À̽þÆ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • ÀÌÁýÆ®

Á¦8Àå ±â¾÷ °³¿ä

  • DuPont Nutrition & Biosciences
  • Jennewein Biotechnologie GmbH
  • Glycom A/S
  • Inbiose NV
  • BASF SE
  • NestléS.A.
  • Abbott Laboratories
  • Glycosyn LLC
  • ZuChem Inc
  • Tereos Starch & Sweeteners
  • Jenica Research Corporation
  • Novalac
  • GlycoUniverse GmbH
  • Biostime International Holdings Limited
  • Clasado Biosciences
KSA 23.11.14

The global human milk oligosaccharides market will grow at a 22.5% CAGR from 2023 to 2032. The increasing awareness of the health benefits of human milk oligosaccharides (HMOs) such as their role in infant immune system development and gut health, will fuel industry growth.

Additionally, the rising prevalence of lactose intolerance and the shift towards breastfeeding alternatives for infants will boost human milk oligosaccharides-based formula sales. According to estimates from MedlinePlus, close to 65% of the human population experiences a decline in the ability to digest lactose post-infancy. Furthermore, ongoing research into potential applications of human milk oligosaccharides in areas like adult nutrition and pharmaceuticals will create new opportunities for business growth.

The increasing partnerships and collaborations between manufacturers of human milk oligosaccharides and producers of infant formula will further augment market growth. This growth will be complemented by the ongoing evolution of regulatory support for the inclusion of human milk oligosaccharides in infant nutrition products. Such developments in cooperation and regulatory endorsement will play a significant role in driving the industry's growth.

The market is segregated based on concentration, application, and region.

Based on concentration, the acidic HMO segment will reflect a substantial CAGR through 2032. The rising awareness of the health benefits of acidic HMO, expanding demand for specialized infant nutrition, and ongoing research demonstrating their advantages in infant health will foster growth in the segment.

The dietary supplement application segment will hold a noteworthy share of the human milk oligosaccharides market by 2032. Factors such as increasing consumer awareness of the potential health benefits of HMOs, their proven prebiotic properties, and the expanding demand for functional and nutritional supplements, particularly those targeting gut health and immune support will drive growth in the segment.

Regionally, the Asia Pacific human milk oligosaccharides (HMOs) market will grow with a commendable CAGR during the analysis period, driven by factors such as increasing birth rates, rising disposable incomes, and a growing emphasis on infant nutrition. Moreover, heightened awareness of the benefits of breastfeeding and the adoption of premium infant formula products will further drive growth in the regional industry.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Industry coverage
  • 1.2 Market scope & definition
  • 1.3 Base estimates & calculations
    • 1.3.1 Data collection
  • 1.4 Forecast parameters
  • 1.5 COVID-19 impact analysis at global level
  • 1.6 Data validation
  • 1.7 Data Sources
    • 1.7.1 Primary
    • 1.7.2 Secondary
      • 1.7.2.1 Paid sources
      • 1.7.2.2 Unpaid sources

Chapter 2 Executive Summary

  • 2.1 Human milk oligosaccharides industry 360 degree synopsis, 2018 - 2032
  • 2.2 Business trends
  • 2.3 Concentration trends
  • 2.4 Application trends
  • 2.5 Regional trends

Chapter 3 Human milk oligosaccharides Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
    • 3.2.2 Industry pitfalls & challenges
  • 3.3 Growth potential analysis
    • 3.3.1 By concentration
    • 3.3.2 By application
  • 3.4 COVID- 19 impact analysis
  • 3.5 Regulatory landscape
    • 3.5.1 U.S.
    • 3.5.2 Europe
  • 3.6 Pricing analysis, 2022
  • 3.7 Technology landscape
    • 3.7.1 Future market trends
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis
  • 3.10 Impact of Russia Ukraine war

Chapter 4 Competitive Landscape, 2022

  • 4.1 Introduction
  • 4.2 Company matrix analysis, 2022
  • 4.3 Global company market share analysis, 2022
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Human milk oligosaccharides Market Size and Forecast, By Concentration 2018 - 2032

  • 5.1 Neutral HMO
  • 5.2 Acidic HMO

Chapter 6 Human milk oligosaccharides Market Size and Forecast, By Application 2018 - 2032

  • 6.1 Infant Formula,
  • 6.2 Dietary Supplements,
  • 6.3 Food and Beverage,
  • 6.4 Others

Chapter 7 Human milk oligosaccharides Market Size and Forecast, By Region 2018 - 2032

  • 7.1 Key trends, by region
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 France
    • 7.3.4 Spain
    • 7.3.5 Italy
  • 7.4 Asia Pacific
    • 7.4.1 Japan
    • 7.4.2 China
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 South Korea
    • 7.4.6 Indonesia
    • 7.4.7 Malaysia
  • 7.5 Latin America
    • 7.5.1 Brazil
    • 7.5.2 Mexico
    • 7.5.3 Argentina
  • 7.6 MEA
    • 7.6.1 South Africa
    • 7.6.2 Saudi Arabia
    • 7.6.3 UAE
    • 7.6.4 Egypt

Chapter 8 Company Profiles

  • 8.1 DuPont Nutrition & Biosciences
  • 8.2 Jennewein Biotechnologie GmbH
  • 8.3 Glycom A/S
  • 8.4 Inbiose NV
  • 8.5 BASF SE
  • 8.6 Nestlé S.A.
  • 8.7 Abbott Laboratories
  • 8.8 Glycosyn LLC
  • 8.9 ZuChem Inc
  • 8.10 Tereos Starch & Sweeteners
  • 8.11 Jenica Research Corporation
  • 8.12 Novalac
  • 8.13 GlycoUniverse GmbH
  • 8.14 Biostime International Holdings Limited
  • 8.15 Clasado Biosciences
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦